Protocol Ledger

NCT03626688 · Phase III · COMPLETED

A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Interventional Phase III clinical trial protocol NCT03626688 sponsored by United Therapeutics in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-01-24 Enrollment: 687 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03626688
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)687 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03626688
Protocol FieldVerified Registry Value
NCT IdentifierNCT03626688
Consolidated Lead SponsorUnited Therapeutics
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment687 participants (ACTUAL)
Registered Start Date2019-01-24
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI